8-K ·Filed May 14, 2026

PROF

Profound Medical Corp.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001171843-26-003441
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor AUA meeting presentations on May 16 for any clinical data readouts that could influence adoption sentiment. The PSMA PET integration initiative is exploratory with no timeline — no near-term revenue impact expected.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
PROF ▲ +0.14% at T+60d
NEUTRAL call ✓ call won +0.14% · α vs SPY -4.37% · entry $6.97 → $6.98
Entry anchored
May 14, 2026
via day open
T+1d
-1.15%
call -1.15% · α -1.09%
$6.89
settled 5mo ago
T+5d
-2.01%
call -2.01% · α -2.97%
$6.83
settled 5mo ago
T+20d
-3.73%
call -3.73% · α -5.85%
$6.71
settled 4mo ago
T+60d
+0.14%
call +0.14% · α -4.37%
$6.98
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Profound Medical issued a press release announcing that its TULSA Procedure will be featured in four oral presentations at the AUA Annual Meeting on May 16, 2026, and that it is launching an initiative to explore integrating PSMA PET molecular imaging with TULSA-PRO for ablation planning. This is a routine conference-related disclosure with no financial data or material operational changes.

Key Facts

  • TULSA Procedure to be highlighted in four oral presentations at AUA Annual Meeting on May 16, 2026
  • Profound launching initiative to explore integration of PSMA PET molecular imaging with TULSA-PRO treatment planning software
  • No financial results, guidance, or material agreements disclosed

Financial Impact

No financial figures disclosed in the filing

Risk Factors

  • PSMA PET integration initiative is exploratory with no guaranteed commercial availability
  • TULSA-PRO compatibility with 0.55T MRI (Siemens Free.Max) not commercially available in all markets, including the US

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-003441
Exhibit: exh_991.htm0001171843-26-003441
Document: 0001171843-26-003441-index-headers.html0001171843-26-003441
Document: 0001171843-26-003441-index.html0001171843-26-003441
Document: 0001171843-26-003441.txt0001171843-26-003441
13 reports for PROF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PROF — sortable, filterable
TypeNow
Sep 4, 2026
28d ago
8-K
NEUTRAL ★ 2/10
$6.89 $5.81▼ −15.67%▼ −14.47%$5.85 (−15.09%)
Sep 3, 2026
29d ago
8-K
NEUTRAL ★ 3/10
$6.80 $5.97▼ −12.21%▼ −11.06%$5.85 (−13.97%)
Aug 17, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$6.55 $6.80▲ +3.82%▲ +5.01%$5.85 (−10.69%)
Aug 17, 2026
6w ago
8-K
NEUTRAL ★ 2/10
$6.55 $6.80▲ +3.82%▲ +5.01%$5.85 (−10.69%)
Jul 24, 2026
10w ago
8-K
BULLISH ★ 6/10
$7.26 $7.25▼ −0.14%▼ −0.51%$5.85 (−19.42%)
Jul 15, 2026
11w ago
8-K
NEUTRAL ★ 2/10
$6.96 $6.99▲ +0.43%▲ +1.41%$5.85 (−15.95%)
May 14, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$6.97 $6.83▼ −2.01%▼ −2.97%$5.85 (−16.07%)
May 12, 2026
20w ago
S-3
NEUTRAL ★ 3/10
$7.10 $6.73▼ −5.21%▼ −4.05%$5.85 (−17.61%)
Apr 16, 2026
24w ago
8-K
NEUTRAL ★ 3/10
$6.62 $6.75▲ +1.96%▲ +0.98%$5.85 (−11.63%)
Apr 14, 2026
24w ago
8-K
NEUTRAL ★ 3/10
$6.26 $6.84▲ +9.27%▲ +7.87%$5.85 (−6.55%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (37h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access